Daniel Hayes, MD, explains the implementation of the American Society of Clinical Oncology's CancerLinQ for beta testing.
Moderator Surabhi Dangi-Garimella asked Daniel Hayes, MD, who has been elected president of the American Society of Clinical Oncology (ASCO) for the term beginning in June 2016, what changes practices would have to adopt to implement ASCO’s CancerLinQ.
Currently, ASCO is rolling out CancerLinQ for beta testing in a number of practices, but he admits they don’t really know how it will function until they put it to work.
“I think as it becomes increasingly more successful, other practices will see the advantages of being enrolled,” he said.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More